Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.
CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is a regenerative and aesthetic medicine company whose news flow centers on its recombinant human collagen (rhCollagen) platform, 3D bioprinting activities and medical aesthetics programs. The company regularly issues updates on its rhCollagen-based BioInk products for 3D bioprinting of tissues and organs, tissue repair solutions and aesthetics-focused product candidates.
Investors following CLGN news can expect coverage of financial results reported via quarterly updates, including revenue trends from business collaborators, BioInk sales and tendon repair and wound healing products. CollPlant also reports on clinical and non-clinical milestones for its photocurable dermal and soft tissue filler program, regenerative breast implant development and its collaboration with AbbVie and Allergan on dermal and soft tissue fillers.
Another key news theme is scientific and research collaborations. CollPlant highlights studies such as the Technion – Israel Institute of Technology comparison of its Collink.3D bioink with Matrigel, and Mayo Clinic’s work on a fully humanized 3D bioprinted skin model using plant-derived rhCollagen. These items illustrate how the company’s materials are used in tissue engineering, disease modeling and non-animal alternatives for preclinical research.
Corporate and commercial updates are also frequent, including announcements about expansion of Vergenix STR tendon-repair product distribution in Europe, establishment of a North American logistics center for rhCollagen and BioInk distribution, and participation in industry conferences and investor events. For readers tracking developments in rhCollagen-based biomaterials, 3D bioprinting and aesthetic medicine, the CLGN news page provides an ongoing stream of company-generated information and regulatory disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Stratasys (SSYS) and CollPlant (CLGN) have announced a joint development and commercialization agreement to focus on bioprinting solutions for regenerative breast implants, targeting a $2.6 billion market opportunity. Utilizing Stratasys' P3 technology and CollPlant's rhCollagen-based bioinks, the partnership aims to produce implants designed to regenerate natural tissue with minimal immune response. The collaboration will also explore the future innovation of additional human tissues and organs. Both companies will cross-promote each other's products to enhance market penetration and capitalize on their respective expertise.
CollPlant Biotechnologies (Nasdaq: CLGN) reported its financial results for the full year 2022, revealing a significant net loss of $16.9 million or $1.53 per share, compared to a profit of $237,000 in 2021. Revenue plummeted to $299,000, a decrease of $15.3 million year-over-year, largely due to a prior $14 million upfront payment from AbbVie. Despite these challenges, CollPlant is advancing its strategic collaboration with AbbVie in developing dermal fillers and is planning further studies for its 3D bioprinted breast implants, targeting a $2.6 billion market. The company ended 2022 with $29.7 million in cash and equivalents.
CollPlant Biotechnologies (CLGN) will release its financial results for the year ended December 31, 2022, on March 29, 2023, before the market opens. Following the release, a conference call will be held at 10:00 am EDT to discuss the results and provide corporate updates. The call can be accessed by U.S. investors at 1-877-407-9716 and by international investors at 1-201-493-6779, with a conference ID of 13736701. CollPlant focuses on regenerative medicine using its proprietary rhCollagen technology, aiming to innovate in tissue repair and organ manufacturing. The company has partnered with Allergan for dermal filler development.